Effects of cyproterone acetate treatment interruption on testicular histology: an experimental rat study relevant to transgender females with incomplete sperm cryopreservation
Öz
Purpose: The aim of this study was to investigate the reversibility of the deterioration of testicles as Cyproterone acetate (CPA) treatment ceased in an experimental rat model, and possible contribution of two angiotensin converting enzyme inhibitors on the process.
Materials and Methods: In the first step, the effects of CPA treatment (14 days) on testicular histology on rats were investigated. In the second step, following the treatment period of 14 days with CPA, the effects of captopril or lisinopril application (for three days or seven days or 14 days) were investigated. Sixty-six rats in eleven groups were investigated. The testicles of the rats were planned to be examined on the following day of the last treatment schedule. Right testicular weight values were recorded. Testicles were histologically evaluated based on light microscopical findings, and also a scoring system was used.
Results: CPA treatment caused weight loss of the testicles, and caused histological scoring value changes. The second step findings revealed that the weight values of the testicles returned to control values in the third day and thereafter. Also, histological scoring values were indifferent compared to control, statistically. Histopathological findings, noted, besides scoring, showed that edema, present in all rats in the seventh day in physiological serum treatment group, was not the case for captopril groups. Also, in captopril groups, no rat with germ cell depletion was observed.
Conclusion: We conclude that the changes in testicular histology were over in the third day in our rat population, and inflammatory reactions or a delay in recovery may be prevented by use of angiotensin converting enzyme inhibitors, especially a thiol-group containing agent, captopril.
Anahtar Kelimeler
captopril, cyproterone acetate, lisinopril, rats Sprague-Dawley, transgender persons, testis
Kaynakça
- Nahata L, Chelvakumar G, Leibowitz S. Gender-affirming pharmacological interventions for youth with gender dysphoria: When treatment guidelines are not enough. Ann Pharmacother. 2017;51:1023–32.
- Kuijpers SME, Wiepjes CM, Conemans EB, Fisher AD, Guy T, Martin den Heijer. Toward a lowest effective dose of cyproterone acetate in trans women: Results from the ENIGI Study. J Clin Endocrinol Metab. 2021;106:e3936–45.
- Warzywoda S, Fowler JA, Wood P, Bisshop F, Russell D, Luu H et al. How low can you go? Titrating the lowest effective dose of cyproterone acetate for transgender and gender diverse people who request feminizing hormones. Int J Transgend Health. 2024;2317395.
- Angus L, Leemaqz S, Ooi O, Cundill P, Silberstein N, Locke P et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect. 2019;8:935–40.
- Muir CA, Guttman-Jones M, Man EJ. Effects of gender affirming hormone treatment in transgender individuals – a retrospective cohort study. Endocrine. 2024;85:370-9.
- Rosenthal SM. Approach to the patient: Transgender youth: Endocrine considerations. J Clin Endocrinol Metab. 2014;99:4379–89.
- Telfer MM, Tollit MA, Pace CC, Pang KC. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. Med J Aust. 2018;209:132–6.
- Jindarak S, Nilprapha K, Atikankul T, Angspatt A, Pungrasmi P, Iamphongsai S et al. Spermatogenesis abnormalities following hormonal therapy in transwomen. Biomed Res Int. 2018;7919481.
- Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102:3869–903.
- O’Connell MA, Nguyen TP, Ahler A, Skinner SR, Pang KC. Approach to the patient: Pharmacological management of trans and gender-diverse adolescents. J Clin Endocrinol Metab. 2021;107:241–57.
